Durable remissions from fludarabine followed by the iodine I-131 tositumomab Bexxar therapeutic regimen for patients with previously untreated follicular non-Hodgkin's lymphoma (NHL).

@article{Leonard2004DurableRF,
  title={Durable remissions from fludarabine followed by the iodine I-131 tositumomab Bexxar therapeutic regimen for patients with previously untreated follicular non-Hodgkin's lymphoma (NHL).},
  author={John P. Leonard and Morton Coleman and Lale Kostakoglu and Amy Chadburn and Jennifer M Fiore and Richard R. Furman and Michael W. Schuster and Stewart M Kroll and Stanley J. Goldsmith},
  journal={Journal of clinical oncology : official journal of the American Society of Clinical Oncology},
  year={2004},
  volume={22 14_suppl},
  pages={6518}
}
6518 Background: The sequential combination of chemotherapy and radioimmunotherapy offers a novel strategy for the initial management of NHL. Tositumomab and iodine I 131 tositumomab (Bexxar) have been demonstrated to have substantial clinical activity in both untreated and relapsed/refractory low-grade NHL. Fludarabine synergizes in vitro with unlabeled and radiolabeled antibodies and can be employed as a "debulking" agent prior to radioimmunotherapy. METHODS Patients with previously… CONTINUE READING